GTC Biotherapeutics (fka GTCB)

[kallevalla]

Next report and conference call for GTCB:

In the Q1 the CC was not recorded and made available to the shareholders (technical problems?). In the Q2 that worked out, but not many questions in the Q&A. In the Q3 questions need to be asked:

1. Leo Pharma/Atryn sales in Europe (When will the sell Atryn in Europe or do they sell in Europe as we speek?)

2. Heparin resistance/FDA process

3. JCOM/Insulin

4. Any interest for the GTC Concept from Pharma co:s, Investors, Healthcare sector in general or any discussions/plans about further financing/deals/selling the company or anything else of interest to the shareholders.

If we ask the questions we may not get the answers but if they choose to not answer at all or give information that later on proves to be wrong or to given late they make temselves vulnerable for lawsuits. It´s time to ask the questions.

Best regards
Kalle